Overview
Novel antibodies in less than 3 months!
SDIX's proprietary Genomic Antibody Technology™ process...
- delivers effective custom antibodies in less than 76 days.
- eliminates the need for protein or peptide antigens.
- lets you provide your DNA sequence online. You needn't ship cDNA, vectors, proteins or anything else.
Genomic Antibody Technology™ (GAT) is a new way to think about protein immunogens. You supply protein sequence information as electronic information. This protein sequence information is placed in SDIX's proprietary plasmid vector. This vector is introduced into rabbits or mice. Cells of the host animal take up the plasmid. In these cells, the immunogen is synthesized and secreted by the host cells and immediately recognized by the immune system. A strong antibody response is the result.
Polyclonal and monoclonal antibodies can be developed using GAT. Polyclonal antibodies are supplied as sera or can be affinity-purified, resulting in an antibody preparation with high specific activity and low background activity.
The protein immunogen is produced in the host animal using natural protein synthesis machinery. Since the immunogen is not synthesized and purified in a laboratory, it does not have the opportunity to denature or degrade. A native immunogen is presented immediately to the immune system, resulting in a mature antibody response.
GAT is able to create reagents where traditional antibody development techniques have failed. Antibodies can be developed to conserved proteins, transmembrane proteins, and membrane-associated proteins, the most difficult classes of protein antigen.
GAT compliments other sequence-based technologies such as nucleic acid microarrays, RNAi, knock-out models, and genomic studies. The sequence information inherent in each of these technologies easily becomes GAT antigen information. GAT also compliments the high-throughput native of sequence-based technologies. Libraries of unique antibody reagents can be delivered simultaneously.
Our Genomic Antibody Technology™ process can produce difficult antibodies faster and at lower cost.
more